Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini... Show more
Revolution Beauty Group, the mass beauty and personal care business behind brands such as REVOLUTION and Makeup Revolution, has spent recent years working through a difficult restructuring. The company returned its co-founders to leadership, cut costs, and exited non-core brands and products after a period of heavy losses. Its fiscal year runs from March to February, making the six months ended 31 August 2026 the first half of fiscal 2027. Because this interim report marks the first half-year period in which the group generated positive adjusted EBITDA, it serves as an important checkpoint on whether the turnaround is genuinely translating into sustainable profitability rather than simply narrower losses.
For the six months ended 31 August 2026, Revolution Beauty reported adjusted EBITDA of £2.0 million, a swing from the £12.5 million loss recorded in the same period a year earlier. Revenue came in at £48.4 million, down about 2% on a headline basis, reflecting the removal of discontinued brands, prior-year clearance activity, and one-off license income. Excluding those items, underlying revenue grew 8.3%.
Gross margin improved materially to 43.6% from 32.2%, helped by the absence of clearance sales, lower gross-to-net charges, and tighter inventory and range management. Operating costs fell roughly 33% to £19.1 million, and the loss before tax narrowed to £1.9 million from £18.4 million. Reported loss per share was GBX 0.20.
Online sales across the company's own website, TikTok Shop, and Amazon rose 22%, driven primarily by TikTok Shop. Net debt declined to £25.7 million from £30.2 million a year earlier, with cash of £4.3 million. Management said September and October trading was in line with expectations and guided toward the top end of full-year market forecasts.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors monitoring turnaround stories like Revolution Beauty, it offers a structured way to surface comparable ideas across the consumer and beauty sectors.
Investor reaction to the interim results was mixed. The shares had rallied strongly in the run-up to the announcement, and the market's focus remained on forward momentum rather than the historical figures. The confirmation of a return to positive adjusted EBITDA, a sharp gross margin improvement, and online sales growth were seen as evidence that the turnaround is progressing. However, the disclosure of a material uncertainty over going concern tempered enthusiasm, highlighting that the group could breach financing covenants in a severe downside scenario unless further mitigating actions succeed. This balance between improving operational trends and lingering balance-sheet risk has kept sentiment cautious even as management described trading as comfortably ahead of expectations.
Management enters the seasonally stronger second half with several growth levers in motion. The company's licensing partnership with Debenhams Group — covering fragrance and gifting under the PrettyLittleThing, Karen Millen, and boohooMAN brands — is expected to launch its first collections ahead of Christmas. Retailer order books are showing early signs of a positive response to range changes, and online channels remain a forward indicator of demand.
Investors will be watching whether gross margin holds in the low-to-mid 40% range, whether the 22% online growth led by TikTok Shop proves sustainable, and whether US and international revenue stabilize after recent declines. The festive trading period represents the next major test of demand.
Balance-sheet resilience remains a central theme. Net debt has fallen, but the going-concern uncertainty means covenant headroom, working capital management, and the outcome of ongoing commercial matters and claims will be closely monitored. The company expects full-year revenue of £92.0 million to £95.0 million and adjusted EBITDA of £6.0 million to £6.6 million, positioning the second half as the decisive period for confirming a durable return to profitable growth.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry Biotechnology